Alnylam Pharmace. buy Oppenheimer Holdings Inc.
Start price
07.01.26
/
50%
€361.70
Target price
07.01.27
€427.30
Performance (%)
-27.26%
Price
05.06.26
€263.10
Summary
This prediction is currently active. The prediction for Alnylam Pharmace. disappoints with a performance of -27.26%. This prediction currently runs until 07.01.27. The prediction end date can be changed by Oppenheimer_Holdings at any time. Oppenheimer_Holdings has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 1.622% | 1.622% |
| iShares Core DAX® | -1,86 % | 0,67 % |
| iShares Nasdaq 100 | -3,32 % | 4,99 % |
| iShares Nikkei 225® | -2,30 % | 6,13 % |
| iShares S&P 500 | -1,31 % | 3,40 % |
Comments by Oppenheimer_Holdings for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $500.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Oppenheimer_Holdings for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€359.70
04.08.25
04.08.25
€423.31
04.08.26
04.08.26
-26.86%
05.06.26
05.06.26
